Clinical trials: Tumor Burden
Carcinoma, Non-Small-Cell Lung
Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings
This non-interventional study will include a representative sample of patients with locally advanced or metastatic NSCLC harboring Epidermal Growth Factor Receptor (EGFR)-mutations in Greece.
- Trial name
- NCT02440854
- Testing
- afatinib
- Where
- 7 sites in Greece
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Indolent Non-Hodgkin's Lymphoma
Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Patients with previously untreated low tumor burden indolent Non-Hodgkin's Lymphoma (NHL) will receive either rituximab or GA101 weekly for 4 weeks followed by re-staging to determine response.
- Trial name
- PrE0401 (NCT01889797)
- Testing
- Arm A: Rituximab, Arm B: GA101
- Where
- 28 sites in United States
- Volunteers
- 32 people
- Sponsor
- PrECOG, LLC.
Follicular Lymphoma, Non-Hodgkin's Lymphoma Follicular
Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy
Patients with high tumor burden, low grade follicular lymphoma that has never been treated, will receive venetoclax in combination with obinutuzumab and bendamustine. Venetoclax is an oral Bcl-2 family protein inhibitor.
- Conditions
- Follicular Lymphoma, Non-Hodgkin's Lymphoma Follicular, Non-Hodgkin's Lymphoma, Adult High Grade
- Trial name
- PrE0403 (NCT03113422)
- Testing
- Induction Venetoclax, Maintenance Venetoclax
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- PrECOG, LLC.
Solid Tumors
Dexamethasone for Symptom Burden in Advanced Cancer Patients
The goal of this clinical research study is to learn if dexamethasone can help to control symptoms such as fatigue, pain, nausea, weight loss, loss of appetite, sleep problems, and/or depression in patients with advanced cancer.
- Trial name
- NCT00489307
- Testing
- Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- M.D. Anderson Cancer Center
Follicular Lymphoma, Small Lymphocytic Lymphoma
A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
Despite strong evidence suggesting that vitamin D deficiency is associated with undesirable outcomes in patients with numerous cancers, there has never been a thorough study of vitamin D treatment in subjects undergoing treatment…
- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mucosal-Associated Lymphoid Tissue Lymphoma
- Trial name
- ILyAD (NCT03078855)
- Testing
- Vitamin D, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 211 people
- Sponsor
- Jonathan Friedberg
Cancer
App-Assisted Day Reconstruction to Reduce Logistic Toxicity in Cancer
The number of new cases of cancer diagnosed in the U.S. was 1.7 million in 2017 and is expected to increase by 35% to 2.3 million in 2030[1].
- Trial name
- NCT05502302
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Non-Small Cell Lung Cancer, Malignant Melanoma
Phase Ib of L-NMMA and Pembrolizumab
The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Non-Small Cell Lung Cancer, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT03236935
- Testing
- L-NMMA, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- The Methodist Hospital Research Institute
Lymphoma
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00075946
- Testing
- rituximab
- Where
- 483 sites in United States
- Volunteers
- 545 people
- Sponsor
- Eastern Cooperative Oncology Group